Proliferative Diabetic Retinopathy Clinical Trial
Official title:
Study of the Association Between Genetic Markers (Endothelial Lipase and Aldose Reductase) and Proliferative Diabetic Retinopathy
Type 2 Diabetes (TD2) is the leading cause of new cases of preventable blindness in these countries (and the gold-standard treatment, laser photocoagulation has proven to be effective in preventing vision loss at the end stage of eye disease due to proliferative diabetic retinopathy (PDR) that occurs in 3 to 6 % of the cases.Therefore, the ongoing search for predictive factors of sight threatening stages of diabetic retinopathy has become more important. Previous studies that have examined candidate predictive factors for diabetic eye disease have mostly focused on systemic risk factors leading to PDR. Among various clinical parameters, increased HbA1c % levels, uncontrolled blood pressure, diabetes duration, neuropathy and elevated triglycerides have been associated with PDR. Some genetic factors may also account for the development of PDR and are prospectively considered in this study .
In a previous study (2011), investigators demonstrated a statistically significant relation between the Endothelial Lipase(EL) c.584C>T polymorphism and the occurrence of diabetic retinopathy in 396 french patients with diabetes type 2 (DT2) with a longitudinal follow-up. Secondly (2014) in a subgroup of 287 DT2 patients, investigators showed the impact of the EL rare T allele was consistent with a recessive mode of inheritance, with homozygotes for the rare allele differing from the carriers of the major allele. Importantly, the homozygotes for the rare T allele were more likely to present with advanced stages of diabetic retinopathy (severe non proliferative and proliferative disease) and particularly with proliferative diabetic retinopathy (PDR). Based on this model investigators decided to conduct a case-control prospective study comparing 155 french patients with DT2 with PDR (cases) and 155 french patients with DT2 without PDR (controls) on the basis of two genetic parameters: EL c.584C>T polymorphism that investigators previously studied and the C(-106)T aldose reductase polymorphism widely studied in diabetic retinopathy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01921192 -
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
|
Phase 4 | |
Recruiting |
NCT01044875 -
Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy
|
N/A | |
Active, not recruiting |
NCT00993525 -
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
|
Phase 1/Phase 2 | |
Completed |
NCT01307072 -
Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT01758757 -
Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy
|
N/A | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Completed |
NCT05408416 -
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
|
N/A | |
Completed |
NCT05414149 -
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
|
N/A | |
Not yet recruiting |
NCT04464694 -
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
|
Phase 4 | |
Not yet recruiting |
NCT03633266 -
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT03490318 -
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
|
||
Completed |
NCT01627977 -
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
|
Phase 3 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00682240 -
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
|
Phase 4 | |
Terminated |
NCT00563628 -
Changes in Macular Thickness After Patterns Scan Laser
|
Phase 4 | |
Terminated |
NCT00563043 -
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
|
Phase 4 | |
Completed |
NCT00446381 -
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
|
N/A | |
Enrolling by invitation |
NCT02911311 -
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
|
N/A | |
Recruiting |
NCT05514925 -
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
|
Phase 4 | |
Completed |
NCT02858076 -
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
|
Phase 2/Phase 3 |